1. Home
  2. CAPR vs BIOX Comparison

CAPR vs BIOX Comparison

Compare CAPR & BIOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • BIOX
  • Stock Information
  • Founded
  • CAPR 2005
  • BIOX 2001
  • Country
  • CAPR United States
  • BIOX Argentina
  • Employees
  • CAPR N/A
  • BIOX N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • BIOX Agricultural Chemicals
  • Sector
  • CAPR Health Care
  • BIOX Industrials
  • Exchange
  • CAPR Nasdaq
  • BIOX Nasdaq
  • Market Cap
  • CAPR 324.6M
  • BIOX 168.3M
  • IPO Year
  • CAPR N/A
  • BIOX N/A
  • Fundamental
  • Price
  • CAPR $6.28
  • BIOX $2.77
  • Analyst Decision
  • CAPR Strong Buy
  • BIOX Strong Buy
  • Analyst Count
  • CAPR 8
  • BIOX 4
  • Target Price
  • CAPR $24.75
  • BIOX $8.38
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • BIOX 279.5K
  • Earning Date
  • CAPR 08-11-2025
  • BIOX 09-08-2025
  • Dividend Yield
  • CAPR N/A
  • BIOX N/A
  • EPS Growth
  • CAPR N/A
  • BIOX N/A
  • EPS
  • CAPR N/A
  • BIOX N/A
  • Revenue
  • CAPR $13,392,150.00
  • BIOX $383,289,394.00
  • Revenue This Year
  • CAPR N/A
  • BIOX N/A
  • Revenue Next Year
  • CAPR $6,061.53
  • BIOX $7.30
  • P/E Ratio
  • CAPR N/A
  • BIOX N/A
  • Revenue Growth
  • CAPR N/A
  • BIOX N/A
  • 52 Week Low
  • CAPR $3.98
  • BIOX $2.60
  • 52 Week High
  • CAPR $23.40
  • BIOX $11.39
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 36.33
  • BIOX 35.91
  • Support Level
  • CAPR $6.17
  • BIOX $2.63
  • Resistance Level
  • CAPR $7.30
  • BIOX $2.89
  • Average True Range (ATR)
  • CAPR 0.43
  • BIOX 0.19
  • MACD
  • CAPR -0.11
  • BIOX 0.02
  • Stochastic Oscillator
  • CAPR 4.53
  • BIOX 30.77

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About BIOX Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.

Share on Social Networks: